Syntekabio, an AI and NGS-based drug development company, announced on Jan. 14 that it has signed multiple co-development agreements with Hanmi Science to develop COVID-19 treatments utilizing drug repositioning technologies.The two companies signed an MOU in September 2020 to develop COVID-19 drug
The Yozma Group Korea announced on June 7 that it would expand its global acceleration program for venture firms in South Korea. Specifically, The Yozma Group Korea is planning to provide mentoring with global experts and make use of its global networks so that their cooperation with older and large
Korean pharmaceutical companies are canceling their plans to attend conferences and marketing events in the United States and Europe as these countries restrict or ban travel to and from Korea due to the spread of the COVID-19 virus.The U.S. Centers for Disease Control (CDC) upgraded its travel aler
The 2020 JP Morgan Healthcare Conference, the world’s largest healthcare investment symposium for the pharmaceutical and biotech industry, opened in San Francisco, the United States, on Jan. 13 (local time), with some 1,500 pharma companies from 40 countries around the world participating. About 30
JW Pharmaceutical will increase its R&D competitiveness by utilizing an artificial intelligence solution.The pharmaceutical firm said on May 2 that it signed a memorandum of understanding (MOU) with Syntekabio on joint research using an artificial intelligence (AI) platform based on genome big data
South Korean biopharmaceutical companies are seeking to develop new drugs with artificial intelligence (AI) technology.According to industry sources on January 3, Seegene Inc. succeeded in developing molecular diagnostic assays by using a newly created AI based assay development system. These assays